Velcade

Drug Overview
Product Profiles
Velcade : Multiple myeloma
Velcade : NHL: Mantle cell lymphoma (MCL)

Figure 1: Velcade for multiple myeloma – SWOT analysis
Figure 2: The authors drug assessment summary of Velcade for multiple myeloma
Figure 3: The authors drug assessment summary of Velcade for multiple myeloma
Figure 4: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Velcade for mantle cell lymphoma – SWOT analysis
Figure 6: The authors drug assessment summary of Velcade in mantle cell lymphoma
Figure 7: The authors drug assessment summary of Velcade in mantle cell lymphoma

Table 1: Velcade drug profile
Table 2: Velcade pivotal trial data in multiple myeloma
Table 3: Velcade late-phase trial data in multiple myeloma
Table 4: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 5: Patients treated with Velcade in the US, Japan, and five major EU markets, by country, 2017–26
Table 6: Velcade drug profile
Table 7: Velcade pivotal trial data in mantle cell lymphoma